TABLE 2.
Drugs identified for PD treatment in zebrafish models.
| Compound | Classification | Model | Effects on phenotype | Behavioral method | Molecular mechanism | References |
|---|---|---|---|---|---|---|
| Trifluoperazine | Piperazine phenothiazine | Rotenone and PINK1-Tg | Protect dopaminergic neurons and mitochondrial function | Touch-evoked escape response, 2 dpf | Stimulate transcription factor EB nuclear translocation and enhance autophagy | Zhang et al. (2017) |
| Ruthenium red | MCU inhibitor | PINK1-Y431*-Tg | Prevent dopaminergic neuronal cell loss | Not applicable | Normalize mitochondrial function | Soman et al. (2017) |
| l-deprenyl | MAO-B inhibitor | MPTP | Protect dopaminergic neurons | Not applicable | Not applicable | McKinley et al. (2005) |
| Minocycline | Tetracycline analog | 6-OHDA | Prevent locomotor deficits and neuronal loss | Light-dark test, 5 dpf | Not applicable | Cronin and Grealy, (2017) |
| Rasagiline | MAO-B inhibitor | 6-OHDA | Prevent the locomotor deficits and neuronal loss | Light-dark test, 5 dpf | Not applicable | Cronin and Grealy, (2017) |
| Melatonin | Methoxy indole | MPTP | Improve motor activity | Locomotion test, 5 dpf | Restore the parkin/Pink1/DJ-1/MUL1 network | Díaz-Casado et al. (2016) |
| Rifampicin | Macrocyclic antibiotic | Rotenone | Improves neuroinflammation and mitochondrial function | Swimming behavior calculated by number of lines crossed, 6 months | Anti-inflammatory | Yurtsever et al. (2020) |
| LP17 | Blocker of TREM-1 | 6-OHDA | Improve locomotion; partially protect dopaminergic neurons | Swimming behavior calculated by moving height, 5 dpf | Activate autophagy and anti-inflammatory | Feng et al. (2019) |
| CsAE | C. siliqua | 6-OHDA | Improve cognitive function | Novel tank diving test, 7 days; Y-maze test, 8 days | Antioxidant and anti-AChE activities | Abidar et al. (2020) |
| Rosmarinic acid | Natural product | MPTP | Protect dopaminergic neurons and improve locomotor behavior | Locomotion test, 5 dpf | Attenuate the increases of ROS via regulation of the DJ-1/Akt/Nrf2 signaling | Zhao et al. (2020) |
| Fucoxanthin | Marine carotenoid | 6-OHDA | Improve the locomotion | Locomotion test, 7 dpf | Decrease ROS levels via regulation of Keap1/Nrf2 signaling | Wu et al. (2021) |
| Naringenin | Flavanone | 6-OHDA | Improve the locomotion | Locomotion test, 7 dpf | Regulate the expression of parkinsonian genes | Kesh et al. (2021a) |
| Theacrine | Purine alkaloid | MPTP | Retrieve dopaminergic neurons loss; improve locomotive activity | Touch-evoked escape response, 5 dpf | Activate SIRT3 | Duan et al. (2020) |
| Hesperidin | Flavanone glycoside | 6-OHDA | Improve locomotion | Locomotion test, 7 dpf | Downregulate lrrk2, gsk3β, casp3 and casp9 | Kesh et al. (2021b) |
| EuO | Eucommia ulmoides Oliver | MPTP | Retrieve the loss of dopaminergic neurons and improve locomotion | Locomotion test, 7 dpf | Activate autophagy and contribute to α-syn degradation | Chen et al. (2020) |
| Hexane | S. mombin | Rotenone | Restore anxiety behavior | Novel tank test; light-dark test, 1 month | Prevent oxidative stress | Santo et al. (2021) |